ES2978392T3 - Sal de adición del agonista del receptor S1P1 y forma cristalina de la misma, y composición farmacéutica - Google Patents

Sal de adición del agonista del receptor S1P1 y forma cristalina de la misma, y composición farmacéutica Download PDF

Info

Publication number
ES2978392T3
ES2978392T3 ES18917186T ES18917186T ES2978392T3 ES 2978392 T3 ES2978392 T3 ES 2978392T3 ES 18917186 T ES18917186 T ES 18917186T ES 18917186 T ES18917186 T ES 18917186T ES 2978392 T3 ES2978392 T3 ES 2978392T3
Authority
ES
Spain
Prior art keywords
formula
compound represented
crystalline form
present application
maleate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES18917186T
Other languages
English (en)
Spanish (es)
Inventor
Wei Zheng
Wubin Pan
Jiawang Guo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Suzhou Connect Biopharmaceuticals Ltd
Original Assignee
Suzhou Connect Biopharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Suzhou Connect Biopharmaceuticals Ltd filed Critical Suzhou Connect Biopharmaceuticals Ltd
Application granted granted Critical
Publication of ES2978392T3 publication Critical patent/ES2978392T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
ES18917186T 2018-05-04 2018-05-04 Sal de adición del agonista del receptor S1P1 y forma cristalina de la misma, y composición farmacéutica Active ES2978392T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2018/085617 WO2019210511A1 (zh) 2018-05-04 2018-05-04 一种s1p1受体激动剂的加成盐及其晶型和药物组合物

Publications (1)

Publication Number Publication Date
ES2978392T3 true ES2978392T3 (es) 2024-09-11

Family

ID=68387039

Family Applications (1)

Application Number Title Priority Date Filing Date
ES18917186T Active ES2978392T3 (es) 2018-05-04 2018-05-04 Sal de adición del agonista del receptor S1P1 y forma cristalina de la misma, y composición farmacéutica

Country Status (13)

Country Link
US (3) US11512078B2 (enExample)
EP (2) EP4353719B1 (enExample)
JP (3) JP7275253B2 (enExample)
KR (2) KR102672632B1 (enExample)
AU (1) AU2018421487B2 (enExample)
CA (1) CA3099196A1 (enExample)
ES (1) ES2978392T3 (enExample)
IL (3) IL278464B2 (enExample)
MX (1) MX2020011665A (enExample)
NZ (1) NZ770323A (enExample)
SG (1) SG11202010969UA (enExample)
WO (1) WO2019210511A1 (enExample)
ZA (1) ZA202007347B (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7275253B2 (ja) * 2018-05-04 2023-05-17 スーチョウ・コネクト・バイオファーマシューティカルズ・リミテッド Ｓ１ｐ１受容体アゴニストの付加塩およびその結晶形態、ならびに薬学的組成物
CA3201000A1 (en) * 2020-11-09 2022-05-12 Arena Pharmaceuticals, Inc. Methods of treating conditions related to the s1p1 receptor

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1549640A4 (en) * 2002-06-17 2008-08-06 Merck & Co Inc 1 - ((5-ARYL-1,2,4-OXADIAZOL-3-YL) BENZYL) AZETIDINE-3-CARBOXYLATE AND 1 - ((5-ARYL-1,2,4-OXADIAZOL-3-YL) BENZYL) PYRROLIDIN-3-CARBOXYLATE AS EDG RECEPTOR AGONISTS
AU2003279915A1 (en) 2002-10-15 2004-05-04 Merck And Co., Inc. Process for making azetidine-3-carboxylic acid
CN103450171B (zh) * 2013-09-22 2015-07-08 苏州康乃德生物医药有限公司 一种免疫调节化合物、其用途和包含其的药物组合物
CN105315266B (zh) 2014-08-01 2019-10-01 苏州康乃德生物医药有限公司 1-{2-氟-4-[5-(4-异丁基苯基)-1,2,4-噁二唑-3-基]-苄基}-3-吖丁啶羧酸的晶型
CN105348276B (zh) 2014-08-22 2020-05-26 苏州康乃德生物医药有限公司 1-{2-氟-4-[5-(4-异丁基苯基)-1,2,4-噁二唑-3-基]-苄基}-3-吖丁啶羧酸的合成方法
CN115772166B (zh) * 2017-01-11 2025-01-03 苏州康乃德生物医药有限公司 一种s1p1受体激动剂的加成盐及其晶型和药物组合物
JP7275253B2 (ja) * 2018-05-04 2023-05-17 スーチョウ・コネクト・バイオファーマシューティカルズ・リミテッド Ｓ１ｐ１受容体アゴニストの付加塩およびその結晶形態、ならびに薬学的組成物

Also Published As

Publication number Publication date
US20250320200A1 (en) 2025-10-16
US12202822B2 (en) 2025-01-21
IL312512A (en) 2024-07-01
IL278464A (enExample) 2021-03-01
IL312512B1 (en) 2025-11-01
CA3099196A1 (en) 2019-11-07
IL278464B1 (en) 2024-06-01
AU2018421487A1 (en) 2020-12-17
KR20240094023A (ko) 2024-06-24
AU2018421487B2 (en) 2024-09-12
EP4353719A1 (en) 2024-04-17
EP3792258A4 (en) 2021-10-06
JP7651198B2 (ja) 2025-03-26
JP2025074350A (ja) 2025-05-13
IL323665A (en) 2025-11-01
US11512078B2 (en) 2022-11-29
BR112020022429A2 (pt) 2021-02-09
EP4353719B1 (en) 2025-12-24
US20230050777A1 (en) 2023-02-16
JP7275253B2 (ja) 2023-05-17
US20210230152A1 (en) 2021-07-29
WO2019210511A1 (zh) 2019-11-07
IL312512B2 (en) 2026-03-01
NZ770323A (en) 2025-12-19
MX2020011665A (es) 2021-01-20
JP2023062091A (ja) 2023-05-02
EP3792258B1 (en) 2024-02-07
SG11202010969UA (en) 2020-12-30
KR102672632B1 (ko) 2024-06-07
EP3792258A1 (en) 2021-03-17
JP2021532165A (ja) 2021-11-25
KR20210019999A (ko) 2021-02-23
IL278464B2 (en) 2024-10-01
ZA202007347B (en) 2021-10-27

Similar Documents

Publication Publication Date Title
CN111164085B (zh) 瑞博西林的共晶和瑞博西林单琥珀酸盐的共晶、其制备方法、组合物和用途
CN116987069B (zh) 呋喹替尼的共晶、其制备方法、组合物和用途
US20250320200A1 (en) Addition salt of s1p1 receptor agonist and crystal form thereof, and pharmaceutical composition
CN110312705B (zh) Gft-505的晶型及其制备方法和用途
CN112778290B (zh) 一种s1p1受体激动剂的加成盐及其晶型和药物组合物
JP2019089822A (ja) トピロキソスタットの新規結晶形及びその製造方法
HK40106546A (en) Addition salt of s1p1 receptor agonist and crystal form thereof, and pharmaceutical composition
RU2822288C2 (ru) Соль присоединения агониста рецептора s1p1 и ее кристаллическая форма и фармацевтическая композиция на ее основе
BR122022025339B1 (pt) Sulfato de agonista de receptor s1p1, forma cristalina do mesmo, seu método de preparação, seu uso, composição farmacêutica que o compreende e método para tratar e/ou prevenir doença mediada pelo receptor s1p1
BR122022025293B1 (pt) Sal de sódio de agonista de receptor s1p1, forma cristalina do mesmo, seu método de preparação, seu uso, composição farmacêutica que o compreende e método para tratar e/ou prevenir doença mediada pelo receptor s1p1
HK40106546B (en) Addition salt of s1p1 receptor agonist and crystal form thereof, and pharmaceutical composition
BR112020022429B1 (pt) Forma cristalina do maleato de agonista de receptor s1p1, seu método de preparação, seu uso e composição farmacêutica que o compreende
HK40042284A (en) Addition salt of s1p1 receptor agonist and crystal form thereof, and pharmaceutical composition
WO2022144042A1 (zh) Tas-116的晶型及其制备方法、药物组合物和用途
HK40042284B (en) Addition salt of s1p1 receptor agonist and crystal form thereof, and pharmaceutical composition
WO2021176216A1 (en) Salts and polymorphic forms of 6-chloro-7-(4-(4-chlorobenzyl)piperazin-1-yl)-2-(1,3-dimethyl-1h-pyrazol-4-yl)-3h-imidazo[4,5-b]pyridine